Evidence map›Paper›PMID 39369222›Full record

ArticleBiology direct2024

Deciphering MOSPD1's impact on breast cancer progression and therapeutic response.

Yiling Jiang, Hailong Li, Sixuan Wu, Baohong Jiang, Lijun Zeng, Yuanbin Tang, Lunqi Luo, Lianjie Ouyang, Wei Du, Yuehua Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology direct, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yiling Jiang *Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, Hunan Province, 421001, People's Republic of China.
Hailong Li *Department of pathology, Changde Hospital, Xiangya School of Medicine, Central South University (The first people's hospital of Changde city), Changde City, 415000, Hunan, People's Republic of China.
Sixuan WuDepartment of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, Hunan Province, 421001, People's Republic of China.
Baohong JiangDepartment of Pharmacy, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, 421001, Hunan, People's Republic of China.
Lijun ZengDepartment of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, Hunan Province, 421001, People's Republic of China.
Yuanbin TangDepartment of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, Hunan Province, 421001, People's Republic of China.
Lunqi LuoDepartment of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, Hunan Province, 421001, People's Republic of China.
Lianjie OuyangDepartment of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, Hunan Province, 421001, People's Republic of China.
Wei DuDepartment of pathology, Changde Hospital, Xiangya School of Medicine, Central South University (The first people's hospital of Changde city), Changde City, 415000, Hunan, People's Republic of China.
Yuehua LiDepartment of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, No. 69 Chuanshan Road, Hengyang, Hunan Province, 421001, People's Republic of China. liyuehua2020@stu.usc.edu.cn.

Funding

Clinical Medical Research 4310 Program of the University of South China 20224310NHYCG07Natural Science Foundation of Hunan Province 2023JJ60495, 2023JJ60496Scientific Research Fund Project of Hunan Provincial Health Commission B202303109577 and D202303109450
6 · The paper itself

Abstract

backgroundMotile Sperm Domain-Containing Protein 1 (MOSPD1) has been implicated in breast cancer (BC) pathophysiology, but its exact role remains unclear. This study aimed to assess MOSPD1 expression levels in BC versus normal tissues and investigate its diagnostic potential.

methodsMOSPD1 expression was analyzed in BC and normal tissues, with Receiver Operating Characteristic analysis for diagnostic evaluation. Validation was performed using immunohistochemistry. Functional studies included tumor growth assays, MOSPD1 suppression and overexpression experiments, and testing BC cell responses to anti-PD-L1 therapy.

resultsMOSPD1 expression was significantly higher in BC samples than normal tissues, correlating with poor clinical outcomes in BC patients. MOSPD1 suppression inhibited tumor growth, while overexpression accelerated it. Silencing MOSPD1 enhanced BC cell sensitivity to anti-PD-L1 therapy and decreased Th2 cell activity. In vivo experiments supported these findings, showing the impact of MOSPD1 on tumor growth and response to therapy.

conclusionsElevated MOSPD1 levels in BC suggest its potential as a biomarker for adverse outcomes. Targeting MOSPD1, particularly with anti-PD-L1 therapy, may effectively inhibit BC tumor growth and modulate immune responses. This study emphasizes the significance of MOSPD1 in BC pathophysiology and highlights its promise as a therapeutic target.

Indexed as

Breast NeoplasmsAnimalsB7-H1 AntigenBiomarkers, TumorCell Line, TumorDisease ProgressionFemaleHumansMiceB7-H1 AntigenBiomarkers, TumorCD274 protein, humanBreast cancerImmune cell infiltrationMOSPD1PD-L1 inhibitorsTh2 cellsTumor microenvironment

Identifiers

PMID39369222
PMCPMC11453086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.